换一批
换一批Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.
第一作者：
Katherine R W,Emary
第一单位：
Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
作者：
Katherine R W,Emary [1]
;
Tanya,Golubchik [2]
;
Parvinder K,Aley [1]
;
Cristina V,Ariani [3]
;
Brian,Angus [4]
;
Sagida,Bibi [1]
;
Beth,Blane [5]
;
David,Bonsall [6]
;
Paola,Cicconi [4]
;
Sue,Charlton [7]
;
Elizabeth A,Clutterbuck [1]
;
Andrea M,Collins [8]
;
Tony,Cox [9]
;
Thomas C,Darton [10]
;
Christina,Dold [1]
;
Alexander D,Douglas [4]
;
Christopher J A,Duncan [11]
;
Katie J,Ewer [4]
;
Amy L,Flaxman [4]
;
Saul N,Faust [12]
;
Daniela M,Ferreira [8]
;
Shuo,Feng [1]
;
Adam,Finn [13]
;
Pedro M,Folegatti [4]
;
Michelle,Fuskova [4]
;
Eva,Galiza [14]
;
Anna L,Goodman [15]
;
Catherine M,Green [16]
;
Christopher A,Green [17]
;
Melanie,Greenland [1]
;
Bassam,Hallis [7]
;
Paul T,Heath [14]
;
Jodie,Hay [18]
;
Helen C,Hill [8]
;
Daniel,Jenkin [4]
;
Simon,Kerridge [1]
;
Rajeka,Lazarus [19]
;
Vincenzo,Libri [20]
;
Patrick J,Lillie [21]
;
Catherine,Ludden [5]
;
Natalie G,Marchevsky [1]
;
Angela M,Minassian [4]
;
Alastair C,McGregor [22]
;
Yama F,Mujadidi [1]
;
Daniel J,Phillips [1]
;
Emma,Plested [1]
;
Katrina M,Pollock [23]
;
Hannah,Robinson [1]
;
Andrew,Smith [24]
;
Rinn,Song [1]
;
Matthew D,Snape [1]
;
Rebecca K,Sutherland [25]
;
Emma C,Thomson [26]
;
Mark,Toshner [27]
;
David P J,Turner [28]
;
Johan,Vekemans [29]
;
Tonya L,Villafana [29]
;
Christopher J,Williams [30]
;
Adrian V S,Hill [4]
;
Teresa,Lambe [1]
;
Sarah C,Gilbert [4]
;
Merryn,Voysey [1]
;
Maheshi N,Ramasamy [31]
;
Andrew J,Pollard [1]
;
COVID-19 Genomics UK consortium ;
AMPHEUS Project ;
Oxford COVID-19 Vaccine Trial Group
作者单位：
Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
[1]
Big Data Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
[2]
Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.
[3]
Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
[4]
COVID-19 Genomics UK, Department of Medicine, University of Cambridge, Cambridge, UK.
[5]
Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
[6]
National Infection Service, Public Health England, Salisbury, UK.
[7]
Department of Clinical Sciences, Liverpool School of Tropical Medicine and Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
[8]
UK Biocentre, Milton Keynes, UK.
[9]
Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK; Department of Infection and Tropical Medicine, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
[10]
Department of Infection and Tropical Medicine, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; Translational and Clinical Research Institute, Immunity and Inflammation Theme, Newcastle University, Newcastle upon Tyne, UK.
[11]
NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust; Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK.
[12]
University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.
[13]
St George's Vaccine Institute, St George's, University of London, London, UK.
[14]
Department of Infection, Guy's and St Thomas' NHS Foundation Trust, St Thomas' Hospital, London, UK; MRC Clinical Trials Unit, University College London, London, UK.
[15]
Clinical BioManufacturing Facility, University of Oxford, Oxford, UK.
[16]
NIHR/Wellcome Trust Clinical Research Facility, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
[17]
University of Glasgow, Glasgow, UK; Lighthouse Laboratory in Glasgow, Queen Elizabeth University Hospital, Glasgow, UK.
[18]
Severn Pathology, North Bristol NHS Trust, Bristol, UK.
[19]
NIHR UCLH Clinical Research Facility, London, UK; NIHR UCLH Biomedical Research Centre, London, UK.
[20]
Hull University Teaching Hospitals NHS Trust, Hull, UK.
[21]
London Northwest University Healthcare, Harrow, UK.
[22]
NIHR Imperial Clinical Research Facility, London, UK; NIHR Imperial Biomedical Research Centre, London, UK.
[23]
College of Medical, Veterinary & Life Sciences, Glasgow Dental Hospital and School, University of Glasgow, Glasgow, UK.
[24]
Clinical Infection Research Group, Regional Infectious Diseases Unit, Western General Hospital, Edinburgh, UK.
[25]
MRC University of Glasgow Centre for Virus Research, Glasgow, UK; Severn Pathology, North Bristol NHS Trust, Bristol, UK; Department of Infectious Diseases, Queen Elizabeth University Hospital, Glasgow, UK.
[26]
Heart Lung Research Institute, Department of Medicine, University of Cambridge, Cambridge, UK; NIHR Cambridge Clinical Research Facility, Cambridge, UK; Cambridge University Hospital and Royal Papworth NHS Foundation Trusts, Cambridge, UK.
[27]
University of Nottingham, Nottingham, UK; Nottingham University Hospitals NHS Trust, Nottingham, UK.
[28]
AstraZeneca BioPharmaceuticals, Gaithersburg, MD, USA.
[29]
Public Health Wales, Cardiff, UK; Aneurin Bevan University Health Board, Newport, UK.
[30]
Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK. Electronic address: maheshi.ramasamy@paediatrics.ox.ac.uk.
[31]
主题词
青少年(Adolescent);成年人(Adult);抗体, 中和(Antibodies, Neutralizing);女(雌)性(Female);人类(Humans);男(雄)性(Male);中年人(Middle Aged);核酸扩增技术(Nucleic Acid Amplification Techniques);疾病大流行(Pandemics);单盲法(Single-Blind Method);病毒载量(Viral Load);青年人(Young Adult)
DOI
10.1016/S0140-6736(21)00628-0
PMID
33798499
发布时间
2024-02-14
- 浏览3
Lancet (London, England)
Lancet (London, England)
1351-1362页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
